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Abstract
Background: Recent research has supported the central role of coagulative factors in advan-
cing atherosclerosis and causing coronary artery disease (CAD). The present study, for the first 
time, aimed to clarify the relationship between R353Q polymorphism for factor VII and the 
occurrence and severity of CAD in a large sample of Iranian population.
Methods: Nine hundred and nineteen consecutive patients with suspected CAD, who candi-
dated for coronary angiography in the Tehran Heart Center between January 2006 and March 
2007, were examined. The number of diseased coronary vessels was determined, and the 
severity of CAD was assessed by the Gensini score. Genotyping was done via the PCR-RFLP 
method.
Results: The frequency of Q and R alleles was 74.1% and 25.9% in the patients with CAD 
and 75.2% and 24.8% in those without CAD, with an insignificant difference (p = 0.625). 
The frequency of Q allele in the patients with single-vessel, two-vessel, and three-vessel diseases 
was 72.8%, 71.5%, and 76.4%, respectively; the difference was also insignificant (p = 0.379). 
No relationship was observed between the distribution of the genotypes and the number of the 
involved coronary vessels. The average of the Gensini score was 43.39 ± 46.18 in the patients 
with QQ genotype, 38.87 ± 42.89 in those with QR genotype, and 55.61 ± 53.80 in the ones 
with RR genotype, with the difference not constituting any statistical significance (p = 0.084).
Conclusions: The results suggest no association between R353Q polymorphism for factor VII  
and the presence or progression of CAD in the Iranian population. (Cardiol J 2013; 20, 5: 
533–538)
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Introduction
Various mechanisms involved in the formation 
of thrombosis and regulation of coagulation have 
been identified to stabilize coronary atheromatous 
plaques. Recent research has supported the central 
role of coagulative factors in advancing atheroscle-
rosis and causing coronary artery disease (CAD) 
[1–3]. In this regard, coagulation factor VII seems 
to have an essential role in the initiation and ex-
tension of coronary atherosclerosis [4, 5]. In the 
coagulation pathway, the main responsibility of fac-
tor VII is the catalysis of factor X, which converts 
prothrombin to thrombin and is an integral part of 
fibrin formation and finalization of the coagulation 
process. In addition, after the appearance of a lesion 
on the vascular membrane, activated factor VII can 
initiate coagulation in association with the tissue 
factor, which is exposed in the vascular lumen and 
therefore facilitates the occurrence of thrombotic 
events. Finally and following misbalancing homeo-
stasis, elevated levels of factor VII increase the 
risk of CAD and also increase the probability of the 
occurrence of myocardial infarction (MI) following 
plaque rupture [6]. Activation and regulation of 
factor VII is potentially affected by both genetic 
and environmental factors. It has been revealed 
that some polymorphisms in factor VII gene can 
lead to the up-regulation or down-regulation of this 
gene and thus change the activation of this factor, 
as well as its level. Recently, R353Q polymorphism 
of factor VII gene has been introduced as a probable 
triggering factor for an increased risk of familial MI 
[7, 8]. However, the reported results are a matter 
of controversy. R353Q polymorphism in exon 8 
involves a missense mutation at codon 353 of the 
gene, resulting in an arginine to glutamine sub-
stitution, which seems to result in a lower risk of 
MI in CAD patients. In a study by Girelli et al. [9], 
patients homozygous for the dominant allele had 
a 72% reduction in activated factor VII activity, 
and the adjusted odds ratio for the occurrence of 
MI among the patients with this allele was 0.47. 
Nevertheless, despite some strong evidence on 
the protective role of R353Q polymorphism, some 
studies have not been able to find any significant 
association between this polymorphism and is-
chemic events in CAD patients [10–13]. This may 
be due to the fact that the gene expression and its 
related polymorphisms can be also influenced by 
some strong environmental factors, as well as by 
the characteristics of the target population [14].
The present study, for the first time, sought 
to clarify the relationship between R353Q poly-
morphism and the occurrence and severity of CAD 
in a large sample of Iranian population.
Methods
Study population
The present study was approved by the Re-
search and Ethics Committee of the Tehran Heart 
Center. A total of 919 consecutive patients with 
suspected CAD, who were candidates for coronary 
angiography in the Tehran Heart Center between 
January 2006 and March 2007, were enrolled. All 
the participants recruited in the study gave their 
informed consent and filled the study questionnaire 
providing information on a variety of variables re-
levant to the assessment of demographics, bioche-
mical markers, such as the lipid profile, and coronary 
risk factors, such as family history of CAD, current 
smoking, hypertension, and diabetes mellitus.
CAD assessment
The existence of coronary lesions was confirmed 
via coronary angiography. Significant coronary stenosis 
was defined according to the guideline of the American 
College of Cardiology/American Heart Association 
(ACC/AHA) as a 50% or more narrowing of the luminal 
diameter in one or more major coronary arteries. CAD 
was defined as the presence of at least one coronary 
vessel with significant stenosis [14]. The number of 
the diseased coronary vessels was also determined, 
and the severity of CAD was assessed using the 
Gensini score, which takes into account the geome-
trical increase in the severity of lesions, cumulative 
effects of multiple obstructions, significance of their 
locations, modifying influence of the collaterals, and 
size and quality of the distal vessels [15].
Measurement of chemical biomarkers
Two fasting blood specimens were collected from 
each patient: one specimen contained the EDETA 
anticoagulant for DNA extraction and the other 
contained no anticoagulant for the lipid profile assay. 
Serum total cholesterol, high-density lipoprotein 
cholesterol (HDL-C), and triglycerides were mea-
sured via enzymatic techniques (Pars Azmoon kits 
accredited by Bioactiva Diagnostica, Germany). The 
Friedewald formula was used to calculate low-density 
lipoprotein cholesterol (LDL-C), except when the 
triglyceride level was greater than 4.52 mmol/L.
Genotyping methodology
Genomic DNA was isolated via the proteinase 
K-buffer method. The polymorphism of the gene 
was analyzed on the basis of polymerase-chain-
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-reaction (PCR) amplification. A PCR RFLP assay 
was performed to detect factor VII R353Q polymor-
ph ism. PCR was performed with a 50 μL reaction 
mixture containing 2 μL of DNA, 10 μM of each 
primer, 2.5 mM of each dNTP, 25 mM of MgCl2, 
5 U/μ of Taq polymerase, and 10XKCl of buffer (MBI, 
Fermentas). Amplification was carried out using 
primers F 5’-GGGAGACTCCCCAAATATCAC-3’, 
and R5’ACGCAGCCTTGGCTTTCTCTC-3’.The 
digested products were visualized on 3% agarose 
gel stained with ethidium bromide.
Statistical analysis
The sample size was determined at 95% con-
fidence interval (CI), 10% precision and 23.0% 
and 13.3% expected prevalence of heterozygote 
genotype in cases and controls, respectively, from 
previous study [16], and found to consist of least 
910 patients. In this regard, the study power was 
also determined at 95.6%. The results are reported 
as mean ± standard deviation (SD) for the quanti-
tative variables and percentages for the categorical 
variables. The groups were compared using the 
Student t-test for the continuous variables and the 
c2 test (or the Fisher exact test if required) for the 
categorical variables. This study was done with the 
power of 90%. A p value £ 0.05 was considered 
statistically significant. All the statistical analyses 
were performed using SPSS version 13.0 (SPSS 
Inc., Chicago, IL, USA) and SAS version 9.1 for 
Windows (SAS Institute Inc., Cary, NC, USA).
Results
A comparison of the baseline characteristics 
and clinical data of the two groups with and without 
CAD (Table 1) showed a higher prevalence rate of 
diabetes mellitus, current smoking, and, to a lesser 
degree, family history of CAD in the former group. 
Also, the serum level of HDL was lower and LDL 
level was higher in the CAD group. However, no 
statistically significant difference was revealed 
between the groups in terms of body mass index, 
prevalence of hypertension, and serum levels of 
triglyceride and total cholesterol.
The results demonstrated no significant dif-
ference in the distribution of the wild (QQ), he-
terozygote (RQ), and homozygous mutant (RR) 
genotypes of factor VII gene in the different sub-
groups of patients’ characteristics (Table 2). On 
the other hand, the distribution of these genotypes 
was not associated with the demographics, the 
presence or absence of CAD risk factors, or the 
level of biochemical markers. The frequency of 
Q and R alleles was 74.1% and 25.9% in the patients 
with CAD, and 75.2% and 24.8% in those without 
CAD, respectively; the difference was insignificant 
(p = 0.625). Regarding the association between the 
alleles of the gene and the severity of CAD (Fig. 1), 
the frequency of Q allele in the patients with single-
-vessel, two-vessel, and three-vessel diseases was 
72.8%, 71.5%, and 76.4%; the difference was not 
significant (p = 0.379). With respect to the distri-
bution of different genotypes of the gene according 
to the severity of CAD (Fig. 2), no relationship was 
observed between the distribution of the genotypes 
and the number of diseased coronary vessels. The 
average of the Gensini score was 43.39 ± 46.18 in 
the patients with QQ genotype, 38.87 ± 42.89 in 
those with QR genotype, and 55.61 ± 53.80 in the 
ones with RR genotype, and the difference was not 
statistically significant (p = 0.084).
Table 1. Baseline characteristics and clinical data of the study population.
Characteristics Without CAD (n = 326) With CAD (n = 593) P
Male gender 169 (51.8) 438 (73.9) < 0.001
Age [year] 56.14/10.32 59.64/10.17 < 0.001
Body mass index [kg/m2] 28.06/4.93 27.53/4.65 0.111
Family history of CAD 66 (20.2) 153 (25.8) 0.059
Diabetes mellitus 69 (21.2) 171 (28.8) 0.011
Hypertension 163 (50.0) 276 (46.5) 0.315
Current smoking 54 (16.6) 147 (24.8) < 0.001
Serum triglyceride 177.28/89.98 180.28/101.90 0.787
Serum cholesterol 185.18/41.35 189.72/46.65 0.199
Serum HDL 45.86/10.64 41.80/10.42 < 0.001
Serum LDL 105.46/38.32 112.87/41.25 0.023
CAD — coronary artery disease; HDL — high-density lipoprotein; LDL — low-density lipoprotein
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Discussion
A comparison between our findings and those 
previously reported in the literature regarding 
the association between factor VII R353Q poly-
morphism and the presence and severity of CAD 
showed contradictory results (Table 3). A review 
of the literature indicates that the results directly 
depend on the racial and genetic characteristics 
of the populations under study and the variety 
of factors affecting the coding of factor VII gene. 
Most of the case-control studies revealing a signi-
ficant association between R353Q polymorphism 
and CAD, consequences of revascularization, or 
post-procedural ischemic events were performed 
on Indian or Indian-Asian populations, while the 
studies carried out on Turkish or European po-
pulations obtained opposite results, which might 
justify the impact of population-based characteri-
stics on the observed differences in the results. In 
a meta-analysis by Mo et al. [7] on the association 
between polymorphisms in the coagulation factor 
VII gene and CAD risk in different ethnicities, it 
was indicated that R353Q polymorphism showed 
a trend for association with CAD only in East 
Asians. In the 36 retrieved studies in their analysis, 
the pooled frequency of Q allele in the CAD cases 
and controls was 12.2% and 12.8%, respectively, 
and it was found to be 14.2% and 8.8% in the con-
trol subjects of Caucasian populations and Asians, 
respectively. Meanwhile, the interactional effects 
of some underlying CAD risk factors on factor VII 
Figure 1. Association between factor VII gene alleles 
and severity of coronary artery disease.
Table 2. Distribution of factor VII genotypes in the different subgroups of the baseline characteristics.
Characteristics QQ (%) RQ (%) RR (%) P
Male gender 327 (64.5) 237 (66.8) 43 (75.4) 0.239
Age [year] 58.28/10.37 58.67/10.46 57.81/9.72 0.762
Body mass index [kg/m2] 27.71/4.88 27.72/4.71 27.81/3.93 0.823
Family history of CAD 119 (23.5) 81 (22.8) 19 (33.3) 0.215
Diabetes mellitus 135 (26.6) 90 (25.4) 15 (26.3) 0.915
Hypertension 240 (47.3) 177 (49.9) 22 (38.6) 0.275
Current smoking 104 (20.6) 84 (23.7) 13 (22.8) 0.699
Serum triglyceride 182.86/93.58 176.01/106.16 166.81/77.95 0.199
Serum cholesterol 190.79/45.53 186.10/44.53 176.81/38.97 0.071
Serum HDL 43.09/10.69 43.58/10.69 42.54/10.57 0.570
Serum LDL 111.63/40.077 109.11/40.33 104.58/36.65 0.340
Abbreviations as in Table 1
Figure 2. Association between factor VII genotypes and 
severity of coronary artery disease.
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gene expression and the activity level of its 
production have been clearly demonstrated. It 
has been reported that factor VII protein level is 
directly associated with triglyceride levels in the 
fasting state so that postprandial increased plasma 
triglycerides can effectively lead to an increase in 
factor VII activation [17]. In addition, plasma levels 
of factor VII are negatively correlated with alcohol 
consumption [18, 19].
Hypertriglyceridemia, as one of the most 
prominent risk factors, is highly prevalent in our 
society. On the other hand, alcohol consumption 
in Iran is far less than that in other communities 
due to religious edicts. Moreover, the increase in 
the number of ischemic events through higher 
levels of activated factor VII is also more prono-
unced in the presence of other additional CAD risk 
factors, including smoking, MI events in family, 
angina pectoris, and high levels of fibrinogen, total 
cholesterol, and LDL-C, as well as low levels of 
HDL-C [20]. In a study by Danielsen et al. [21], 
factor VII concentration and activation was lower 
Table 3. Review of case-control studies on the association between factor VII coronary artery disease (CAD).
Author, year Population Case-control design Significance 
Criado-García, 2011 European 720 patients (546 with family history  
and 174 controls) from Spain
0
Sobti, 2010 Indian CHD patients (n = 300) and their  
age-matched controls (n = 300)
1
Shanker, 2009 Indian 139 Indian families with CAD, comprising  
222 affected subjects, 105 unaffected  
subjects and 126 affected sibling pairs
1
Taymaz, 2007 Turkish 137 CAD patients with early onset documented 
by coronary angiography and 41 individuals 
who had no significant coronary stenosis 
0
Quek, 2006 Asian-Indian 561 Chinese, 398 Malays and 226 Asian Indians 
from Singapore
1
Jeffery, 2005 European 519 cases, 400 had no previous MI  
or revascularization, including  
153 with zero-vessel disease
1
Lu, 2005 Chinese 108 elderly patients with CHD and 120 sex-  
and age-matched healthy control subjects
1
Pegoraro, 2005 Indian Asians 195 unrelated patients (£ 45 years)  
with MI 107 unaffected siblings (18–45 years) 
and 300 healthy age- and race-matched  
control subjects 
1
Lindman, 2004 European 560 elderly men characterized  
as hypercholesterolemic 
1
Carew, 2003 American 1957 men 1
Xu, 2003 Chinese Han 234 CHD patients and 210 controls 1
Liu, 2002 Chinese 209 male and 214 female healthy  
Chinese individuals 
1
Petrovic, 2001 Slovene 167 patients with CAD younger than 55 years 
were compared with 132 healthy subjects
1
Jimenez-Boj, 2000 Australian 111 patients with angiographically documented 
acute coronary syndromes and 108 age-  
and sex-matched individuals 
0
Lievers, 2000 European 511 male patients of the Regression  
Growth Evaluation Statin Study 
0
Song, 2000 Korean 139 normal adults and 158 patients with CAD 0
Hegele, 1997 Alberta  
Hutterites
– 1
Wang, 1997 Australian 545 white Australian patients (388 male  
and 157 female) aged £ 65 years
0
Saha, 1994 Indian 185 healthy Dravidian Indians  
of both sexes (128 men, 57 women)
1
CHD — coronary heart disease; MI — myocardial infarction
538 www.cardiologyjournal.org
Cardiology Journal 2013, Vol. 20, No. 5
in patients with previous MI, higher in women and 
those having previously undergone percutaneous 
transluminal coronary angioplasty, and also positi-
vely related to total cholesterol, duration of CAD, 
and smoking.
All in all, to explain the association between 
different polymorphisms in factor VII and CAD 
severity, it is reasonable to consider the pivotal 
role of the underlying potential factors, including 
ethnicity and CAD risk factors.
Conclusions
According to our findings, it can be concluded 
that factor VII R353Q polymorphism has no me-
aningful association with the presence and seve-
rity of CAD in the Iranian population. Given that 
our center is a referral center for cardiovascular 
disease in the country, our study population was 
an appropriate example of our community and the 
results can be generalized to other parts of the 
country as well.
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